Sodium (R)-alpha-lipoate
- CAS NO.：176110-81-9
- Empirical Formula: C8H15NaO2S2
- Molecular Weight: 230.32
- MDL number: MFCD29919437
- EINECS: 229-567-4
- Update Date: 2025-09-01 20:28:32
What is Sodium (R)-alpha-lipoate?
The Uses of Sodium (R)-alpha-lipoate
Sodium (R)-alpha-lipoate is a potent antioxidant used to correct diabetic neuropathy and avoid nerve damage by enhancing glucose metabolism and reducing oxidative stress. In addition, it has a potential role in the treatment of Alzheimer's disease and multiple sclerosis.
Properties of Sodium (R)-alpha-lipoate
| InChI | InChI=1/C8H14O2S2.Na.H/c9-8(10)4-2-1-3-7-5-6-11-12-7;;/h7H,1-6H2,(H,9,10);;/t7-;;/s3 |
Safety information for Sodium (R)-alpha-lipoate
Computed Descriptors for Sodium (R)-alpha-lipoate
| InChIKey | WRBKEAUOTGDJNP-DCFBZVEJNA-N |
| SMILES | C([C@H]1SSCC1)CCCC(=O)O.[NaH] |&1:1,r| |
New Products
2-(2-aminoethyl) benzenesulfonamide Gemcitabine 3-benzoate impurity Dihydroxyphenylacetone Ornidazole EP impurity D Acetyl amino diol impurity Valsartan Benzyl Ester Impurity B N,N'-Dicyclohexylcarbodiimide 3-Bromo-2-Methyl-5-Nitropyridine 5-Bromo-3-Methyl-2-Pyridinecarboxylic acid 2-Amino-4-Methylpyridine 4-Aminopyridine 4-dimethylaminopyridineRelated products of tetrahydrofuran
You may like
-
4-(Methylnitrosoamino)-butanal NLT 95%View Details
339362-86-6 -
848696-99-1 NLT 95%View Details
848696-99-1 -
Ornidazole EP impurity A 1384752-15-1 NLT 95%View Details
1384752-15-1 -
615-81-6 Diisopropyl oxalate NLT 95%View Details
615-81-6 -
175481-38-6 Lacosamide EP Impurity F NLT 95%View Details
175481-38-6 -
S-Clopidogrel N-Methyl Impurity 1346605-15-9 NLT 95%View Details
1346605-15-9 -
Valsartan Related Compound A NLT 95%View Details
137862-87-4 -
Losartan Propyl BCFI 124750-49-8 NLT 95%View Details
124750-49-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.